Publications & Meeting Contributions

Publications & science

2025

ETOP 13-18 BEAT-meso

xx. Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, Shah R, de Marinis F, Cove Smith L, Bernabé R, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Nadal E, Vila Martinez L, Talbot T, Roschitzki-Voser H, Dimopoulou G, Schär S, Ruepp B, Savic S, Peters S, and Stahel R. A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial. Ann Oncol 2025. Doi:10.1016/j.annonc.2024.12.014/Epub Date: 2025/01/16. (ETOP 13-18 BEAT-meso) (Journal Impact Factor 56.7)

ETOP 15-19 ABC-lung

43. Soo RA, Vervita K, Früh M, Cho BC, Majem M, Rodriguez Abreu D, Ribi K, Callejo A, Moran T, Domine Gomez M, Provencio M, Addeo A, Han JY, Ortega Granados AL, Reck M, Blasco A, Garcia Campelo R, Sala González MA, Britschgi C, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Haberecker M, Dafni U, Peters S, and Stahel RA. A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. Lung Cancer 2025; 202:108454. Doi:10.1016/j.lungcan.2025.108454/Epub Date: 2025/03/03. (ETOP 15-19 ABC-lung) (Journal Impact Factor 4.5)

ETOP Mesoscape

42. Haberecker M, Rüschoff JH, Andriakopoulou C, Gray SG, Nackaerts K, De Perrot M, Brcic L, Nadal E, Tsimpoukis S, Ampollini L, Aerts JG, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, Von Der Thüsen J, Vagenknecht P, Tsourti Z, Kerr KM, Kammler R, Peters S, Baas P, Opitz I, Stahel RA, and Curioni-Fontecedro A. Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results from the European Thoracic Platform Mesoscape Project. JCO Precis Oncol 2025; 9:e2400675. Doi:10.1200/po-24-00675/Epub Date: 2025/02/12. (ETOP Mesoscape) (Journal Impact Factor 5.3)

ETOP 19-21 USZ-STRIKE

41. Weller M, Le Rhun E, Tsamtsouri L, Dummer R, Guckenberger M, Ribi K, di Giacomo AM, Minuti G, Collazo-Lorduy A, Brandsma D, O'Brien M, Ermis E, Fischer N, Ascierto P, Mandala M, Minniti G, Iranzo P, Roschitzki-Voser H, Ruepp B, Grolimund E, Dafni U, Peters S, and Stahel R. Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study. Lung Cancer 2025; 199:108069. Doi:10.1016/j.lungcan.2024.108069/Epub Date: 2024/12/29. (ETOP 19-21 USZ-STRIKE) (Journal Impact Factor 4.5)

2024

ETOP 10-16 BOOSTER

40. Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, and Stahel RA. ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. Clin Cancer Res 2024;30:(22),5180-5191. Doi:10.1158/1078-0432.ccr-24-0932/Epub Date: 2024/09/09. (ETOP 10-16 BOOSTER) (Journal Impact Factor 10.4)

ETOP Lungscape

39. Speel EM, Dafni U, Thunnissen E, Hendrik Rüschoff J, O'Brien C, Kowalski J, Kerr KM, Bubendorf L, Sansano I, Joseph L, Kriegsmann M, Navarro A, Monkhorst K, Bille Madsen L, Hernandez Losa J, Biernat W, Stenzinger A, Rüland A, Hillen LM, Marti N, Molina-Vila MA, Dellaporta T, Kammler R, Peters S, Stahel RA, Finn SP, and Radonic T. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project. Lung Cancer 2024; 194:107860. Doi:10.1016/j.lungcan.2024.107860/Epub Date: 2024/07/14. (ETOP Lungscape) (Journal Impact Factor 4.5)

ADC Workshop 2023

38. Peters S, Loi S, André F, Chandarlapaty S, Felip E, Finn SP, Jänne PA, Kerr KM, Munzone E, Passaro A, Pérol M, Smit EF, Swanton C, Viale G, and Stahel RA. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation. Ann Oncol 2024; 35:(7), 607-629. Doi:10.1016/j.annonc.2024.04.002/Epub Date: 2024/04/23. (ETOP General) (Journal Impact Factor 56.7)

2023

ETOP 9-15 PROMISE-meso

37. Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, and Stahel RA. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma. J Immunother Cancer 2023; 11:(10). Doi:10.1136/jitc-2023-007585/Epub Date: 2023/10/26. (ETOP 9-15 PROMISE-meso) (Journal Impact Factor 10.9)

ETOP MESOSCAPE

36. Opitz I, Bille A, Dafni U, Nackaerts K, Ampollini L, de Perrot M, Brcic L, Nadal E, Syrigos K, Gray SG, Aerts J, Curioni-Fontecedro A, Rüschoff JH, Monkhorst K, Weynand B, Silini EM, Bavaghar-Zaeimi F, Jakopovic M, Llatjos R, Tsimpoukis S, Finn SP, von der Thüsen J, Marti N, Dimopoulou G, Kammler R, Peters S, Stahel RA, Falcoz PE, Brunelli A, and Baas P. European Epidemiology of Pleural Mesothelioma-Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database. J Thorac Oncol 2023; 18:(9), 1233-1247. Doi:10.1016/j.jtho.2023.06.011/Epub Date: 2023/06/26. (ETOP Mesoscape) (Journal Impact Factor 21.0)

ETOP 11-16 NIVOTHYM

35. Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, Popat S, Janssens A, Gervais R, Hochstenbag M, Silva M, Burger IA, Prosch H, Stahel R, Xenophontos E, Pretzenbaher Y, Neven A, and Peters S. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open 2023; 8:(3), 101576. Doi:10.1016/j.esmoop.2023.101576/Epub Date: 2023/06/08. (ETOP 11-16 NIVOTHYM) (Journal Impact Factor 7.3)

ETOP 05-12 SPLENDOUR

34. Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N, Majem Tarruella M, Casas-Martin J, Tsourti Z, Marti N, Kammler R, Danson S, O'Brien M, and Stahel RA. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial. Lung Cancer 2023; 175:141-151. Doi:10.1016/j.lungcan.2022.12.004/Epub Date: 2022/12/20. (ETOP 5-12 SPLENDOUR) (Journal Impact Factor 4.5)

2022

ETOP 8-15 PEARLS

33. O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, and Peters S. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022; 23:(10), 1274-1286. Doi:10.1016/s1470-2045(22)00518-6/Epub Date: 2022/09/16. (ETOP 8-15 PEARLS) (Journal Impact Factor 51.1)

ETOP Mesoscape

32. Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, Nadal E, Tsimpoukis S, Gray SG, Ampollini L, Aerts JG, Felley-Bosco E, Kirschner MB, Monkhorst K, Weynand B, Bavaghar-Zaeimi F, Samarzija M, Llatjos R, Finn SP, Silini E, von der Thüsen J, Marti N, Vervita K, Kammler R, Peters S, Stahel RA, Baas P, and Opitz I. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project. Mod Pathol 2022; 35:(12), 1888-1899. Doi:10.1038/s41379-022-01145-0/Epub Date: 2022/09/18. (ETOP Mesoscape) (Journal Impact Factor 8.209)

ETOP Lungcape

31. Bubendorf L, Zoche M, Dafni U, Rüschoff JH, Prince SS, Marti N, Stavrou A, Kammler R, Finn SP, Moch H, Peters S, and Stahel RA. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort. Lung Cancer 2022; 174:27-35. Doi:10.1016/j.lungcan.2022.09.014/Epub Date: 2022/10/26. (ETOP Lungscape) (Journal Impact Factor 5.3)

ETOP 12-17 ALERT-lung

30. Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans A-MC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, and Stahel R. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. Lung Cancer 2022; 172:94-99. Doi:https://doi.org/10.1016/j.lungcan.2022.08.008/Epub Date: 2022/08/12. (ETOP 12-17 ALERT-lung) (Journal Impact Factor 5.3)

ETOP 9-15 PROMISE-meso

29. Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, and Stahel RA. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial. Lung Cancer 2022; 169:77-83. Doi:10.1016/j.lungcan.2022.05.018/Epub Date: 2022/06/07. (ETOP 9-15 PROMISE-meso) (Journal Impact Factor 5.3)

ETOP 10-16 BOOSTER

28. Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, Han JY, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Sala MA, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, and Stahel RA. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open 2022; 7:(3), 100507. Doi:10.1016/j.esmoop.2022.100507/Epub Date: 2022/06/14. (ETOP 10-16 BOOSTER) (Journal Impact Factor 5.73)

General

27. Pérol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel R, and Peters S. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol 2022; 33:(5), 511-521. Doi:10.1016/j.annonc.2022.02.008/Epub Date: 2022/02/27. (ETOP General) (Journal Impact Factor 50.5)

ETOP 10-16 BOOSTER

26. Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, and Peters S. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2022; 33:(2), 181-192. Doi:10.1016/j.annonc.2021.11.010/Epub Date: 2021/11/29. (ETOP 10-16 BOOSTER) (Journal Impact Factor 50.5)

ETOP 4-12 STIMULI

25. Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Mollá A, Gervais R, López Vivanco G, Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, González Larriba JL, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, and De Ruysscher D. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol 2022; 33:(1), 67-79. Doi:10.1016/j.annonc.2021.09.011/Epub Date: 2021/09/26. (ETOP 4-12 STIMULI) (Journal Impact Factor 50.5)

2021

ETOP 5-12 SPLENDOUR

24. Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, and O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung Cancer 2021; 161:76-85. Doi:10.1016/j.lungcan.2021.09.002/Epub Date: 2021/09/21. (ETOP 5-12 SPLENDOUR) (Journal Impact Factor 6.081)

ETOP Lungscape

23. Finn SP, Addeo A, Dafni U, Thunnissen E, Bubendorf L, Madsen LB, Biernat W, Verbeken E, Hernandez-Losa J, Marchetti A, Cheney R, Warth A, Speel EM, Quinn AM, Monkhorst K, Jantus-Lewintre E, Tischler V, Marti N, Dimopoulou G, Molina-Vila MA, Kammler R, Kerr KM, Peters S, and Stahel RA. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol 2021; 16:(6), 990-1002. Doi:10.1016/j.jtho.2021.02.016/Epub Date: 2021/03/02. (ETOP Lungscape) (Journal Impact Factor 20.121)

ETOP 6-14 NICOLAS

22. Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, and De Ruysscher D. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol 2021; 16:(2), 278-288. Doi:10.1016/j.jtho.2020.10.129/Epub Date: 2020/11/15. (ETOP 6-14 NICOLAS) (Journal Impact Factor 20.121)

2020

ETOP 9-15 PROMISE-meso

21. Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur WD, López Castro R, García Campelo R, Rusakiewicz S, Letovanec I, Polydoropoulou V, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Peters S, and Stahel RA. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2020; 31:(12), 1734-1745. Doi:10.1016/j.annonc.2020.09.009/Epub Date: 2020/09/26. (ETOP 9-15 PROMISE-meso) (Journal Impact Factor 32.976)

ETOP 5-12 SPLENDOUR

20. Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Rabaglio M, O'Brien MER, and Stahel RA. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. J Thorac Oncol 2020; 15:(10), 1647-1656. Doi:10.1016/j.jtho.2020.06.011/Epub Date: 2020/06/23. (ETOP 5-12 SPLENDOUR) (Journal Impact Factor 15.609)

General

19. Stahel RA, Lacombe D, Cardoso F, Casali PG, Negrouk A, Marais R, Hiltbrunner A, and Vyas M. Current models, challenges and best practices for work conducted between European academic cooperative groups and industry. ESMO Open 2020; 5:(2). Doi:10.1136/esmoopen-2019-000628/Epub Date: 2020/03/28. (ETOP General) (Journal Impact Factor 5.329)

ETOP 2-11 BELIEF

18. Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Curioni Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Ponce Aix S, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, and Rosell R. Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. J Thorac Oncol 2020; 15:(3), 416-425. Doi:10.1016/j.jtho.2019.11.023/Epub Date: 2019/12/10. (ETOP 2-11 BELIEF) (Journal Impact Factor 15.609)

ETOP Lungscape

17. Thunnissen E, Kerr KM, Dafni U, Bubendorf L, Finn SP, Soltermann A, Biernat W, Cheney R, Verbeken E, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Tsourti Z, Geiger T, Kammler R, Peters S, and Stahel RA. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. Mod Pathol 2020; 33:(5), 792-801. Doi:10.1038/s41379-019-0383-9/Epub Date: 2019/11/20. (ETOP Lungscape) (Journal Impact Factor 7.842)

2019

ETOP Fixation Effects

16. van Seijen M, Brcic L, Gonzales AN, Sansano I, Bendek M, Brcic I, Lissenberg-Witte B, Korkmaz HI, Geiger T, Kammler R, Stahel R, and Thunnissen E. Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen. Virchows Arch 2019; 475:(2), 191-199. Doi:10.1007/s00428-019-02595-9/Epub Date: 2019/07/03. (ETOP Fixation Effects) (Journal Impact Factor 2.935)

General

15. Dafni U, Tsourti Z, Vervita K, and Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer 2019; 134:127-140. Doi:10.1016/j.lungcan.2019.05.029/Epub Date: 2019/07/20. (ETOP General) (Journal Impact Factor 7.702)

ETOP 6-14 NICOLAS

14. Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, and De Ruysscher D. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer 2019; 133:83-87. Doi:10.1016/j.lungcan.2019.05.001/Epub Date: 2019/06/16. (ETOP 6-14 NICOLAS) (Journal Impact Factor 4.702)

ETOP 7-14 NICHE

13. Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, and Peters S. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol 2019; 14:(6), 1086-1094. Doi:10.1016/j.jtho.2019.02.017/Epub Date: 2019/03/03. (ETOP 7-14 NICHE) (Journal Impact Factor 13.357)

ETOP Lungscape

12. Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, and Stahel R. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer 2019; 131:95-103. Doi:10.1016/j.lungcan.2019.03.012/Epub Date: 2019/04/28. (ETOP Lungscape) (Journal Impact Factor 4.702)

2018

ETOP Lungscape

11. Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, and Soltermann A. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. J Thorac Oncol 2018; 13:(12), 1851-1863. Doi:10.1016/j.jtho.2018.08.2034/Epub Date: 2018/09/22. (ETOP Lungscape) (Journal Impact Factor 12.46)

ETOP Lungscape

10. Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, and Peters S. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol 2018; 13:(3), 413-425. Doi:10.1016/j.jtho.2017.11.117/Epub Date: 2017/12/02. (ETOP Lungscape) (Journal Impact Factor 12.46)

ETOP Lungscape

9. Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, and Peters S. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Ann Oncol 2018; 29:(1), 200-208. Doi:10.1093/annonc/mdx629/Epub Date: 2017/12/01. (ETOP Lungscape) (Journal Impact Factor 14.196)

2017

ETOP Lungscape

8. Bubendorf L, Dafni U, Schöbel M, Finn SP, Tischler V, Sejda A, Marchetti A, Thunnissen E, Verbeken EK, Warth A, Sansano I, Cheney R, Speel EJM, Nonaka D, Monkhorst K, Hager H, Martorell M, Savic S, Kerr KM, Tan Q, Tsourti Z, Geiger TR, Kammler R, Schulze K, Das-Gupta A, Shames D, Peters S, and Stahel RA. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer 2017; 111:143-149. Doi:10.1016/j.lungcan.2017.07.021/Epub Date: 2017/08/26. (ETOP Lungscape) (Journal Impact Factor 4.486)

ETOP 2-11 BELIEF

7. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, and Stahel RA. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:(5), 435-444. Doi:10.1016/s2213-2600(17)30129-7/Epub Date: 2017/04/15. (ETOP 2-11 BELIEF) (Journal Impact Factor 19.287)

ETOP 3-12 EMPHASIS-lung

6. Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, and Smit EF. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. J Thorac Oncol 2017; 12:(4), 752-762. Doi:10.1016/j.jtho.2016.12.017/Epub Date: 2016/12/27. (ETOP 3-12 EMPHASIS-lung) (Journal Impact Factor 5.04)

2014

ETOP Lungscape

5. Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O'Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, and Stahel RA. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol 2014; 9:(11), 1675-1684. Doi:10.1097/jto.0000000000000320/Epub Date: 2014/12/02. (ETOP Lungscape) (Journal Impact Factor 5.282)

ETOP Lungscape

4. Blackhall FH, Peters S, Bubendorf L, Dafni U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, Hernández-Losa J, Marchetti A, Savic S, Tan Q, Thunnissen E, Speel EJ, Cheney R, Nonaka D, de Jong J, Martorell M, Letovanec I, Rosell R, and Stahel RA. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 2014; 32:(25), 2780-2787. Doi:10.1200/jco.2013.54.5921/Epub Date: 2014/07/30. (ETOP Lungscape) (Journal Impact Factor 18.428)

ETOP Lungscape

3. Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel R, and Thunnissen E. Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer 2014; 111:(2), 413-420. Doi:10.1038/bjc.2014.353/Epub Date: 2014/07/02. (ETOP Lungscape) (Journal Impact Factor 4.836)

2011

General

2. Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, and de Marinis F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer 2011; 74:(3), 544-548. Doi:10.1016/j.lungcan.2011.08.013/Epub Date: 2011/10/01. (ETOP General) (Journal Impact Factor 3.356)

2010

General

1. Stahel R, Baas P, Faivre-Finn C, Dooms C, Passlick B, Mazières J, Cappuzzo F, Früh M, Sorensen JB, Blackhall F, Taron M, Gridelli C, O'Byrne K, and Rosell R. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer 2010; 68:(1), 121-124. Doi:10.1016/j.lungcan.2010.01.010/Epub Date: 2010/02/09. (ETOP General) (Journal Impact Factor 3.356)

2024

ETOP 19-21 USZ-STRIKE

51. Weller M, Rhun EL, Giacomo AMD, Mayinger M, Roschitzki H, Guckenberger M, Ruepp B, Dummer R, Dafni U, Maio M, and Stahel R. OCTS-02 ETOP 19-21 USZ-STRIKE: Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer. Neuro-Oncology Advances 2024;6:(Supplement_1),i26-i26. Presented at the 2024 SNO/ASCO CNS Metastases Conference, Denver, Colorado, USA. (ETOP 19-21 USZ-STRIKE)

ETOP 14-18 CHESS

50. Guckenberger M, Opitz I, Dellaporta MT, Curioni-Fontecedro A, Frauenfelder T, Cerciello F, Sullivan I, Hendriks L, Dorta M, Callejo A, Aerts J, Addeo A, Dingemans A-M, Pasello G, Provencio M, Ribi K, de Marinis F, Mederos N, Roschitzki-Voser H, Ruepp B, Kammler R, Tsourti Z, Peters S, and Stahel RA. 178: Multimodality treatment in synchronous oligometastatic NSCLC: final analysis of the ETOP CHESS trial. Radiotherapy and Oncology 2024;194:S1586-S1588. Presented at the ESTRO 2024 in Glasgow, United Kingdom. (ETOP 14-18 CHESS)

ETOP 4-12 STIMULI

49. Homicsko K, Abdelhamid K, Vervita K, Marcone R, Andrade J, Becker-Commissaris A, Pujol J-L, Sr. MD, Popat S, Reck M, Pechoux CL, Ruysscher DD, Kammler R, Finn SP, Stahel RA, and Peters S. Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer. Journal of Clinical Oncology 2024;42:(16_suppl),8103-8103. Presented at the ASCO Annual Meeting 2024. (ETOP 4-12 STIMULI)

ETOP 13-18 BEAT-meso

48. Popat S, Felip E, Dafni U, Pope A, Perez SC, Shah RNH, Marinis Fd, Smith LC, Caro RB, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Schaer S, Prince SS, Roschitzki-Voser H, Ruepp B, Peters S, Stahel RA, and Collaborators ftE-B-m. BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM) – Results from the ETOP 13-18 trial. 2024;42:(17_suppl),LBA8002-LBA8002. Presented at the ASCO Annual Meeting 2024. (ETOP 13-18 BEAT-meso)

ETOP 15-18 ABC-lung

47. Frueh M, Soo RA, Vervita A, Cho BC, Majem M, Rodriguez Abreu D, Callejo Perez A, Moran Bueno MT, Domine Gomez M, Provencio Pulla M, Addeo A, Han JY, Ortega Granados ALO, Ribi K, Roschitzki-Voser H, Ruepp B, Haberecker M, Dafni U, Peters S, and Stahel RA. 12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial. ESMO Open 2024;9. Presented at the European Lung Cancer Congress (ELCC) 2024 in Prague. (ETOP 15-19 ABC-lung)

2023

ETOP 9-15 PROMISE-meso

46. Homicsko K, Zygoura G, Tissot S, Popat S, Curioni-Fontecedro A, Dellaporta T, O'Brien M, Pope A, Shah RNH, Kammler R, Finn SP, Coukos G, Peters S, and Stahel RA. Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma. Journal of Clinical Oncology 2023;41:(16_suppl),e20545-e20545. Presented at the ASCO Annual Meeting 2023. (ETOP 9-15 PROMISE-meso)

ETOP Lungscape

45. Speel EJM, Radonic T, Dafni U, Thunnissen E, Rüschoff JH, Kowalski J, Kerr KM, Bubendorf L, Valero IS, Joseph L, Navarro A, Monkhorst K, Madsen LB, Losa JH, Biernat W, Dellaporta T, Kammler R, Peters S, Stahel RA, and Finn SP. 191P ROS1 fusions in resected stage I-III adenocarcinoma (ADC): A Lungscape ETOP study. Journal of Thoracic Oncology 2023;18:(4),S144-S145. Presented at the European Lung Cancer Congress (ELCC) 2023 in Copenhagen. (ETOP Lungscape)

ETOP 10-16 BOOSTER

44. Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Gonzalez MAS, Coate L, Pulla MP, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, and Stahel RA. 16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial. Journal of Thoracic Oncology 2023;18:(4),S49-S50. Presented at the ELCC 2023 in Copenhagen. (ETOP 10-16 BOOSTER)

2022

ETOP 9-15 PROMISE-meso

43. Homicsko K, Zygoura P, Tissot S, Norkin M, Popat S, Curioni-Fontecedro A, O'Brien MER, Pope T, Shah R, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, and Stahel RA. 11P Association of VISTA-expressing CD66b-positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma. Immuno-Oncology and Technology 2022;16. Presented at the ESMO Immuno-Oncology and Technology Congress (IOTECH) December 2022. (ETOP 9-15 PROMISE-meso)

ETOP 8-15 PEARLS

42. Paz-Ares L, O'Brien MER, Mauer M, Dafni U, Oselin K, Havel L, Esteban Gonzalez E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Keller SM, Jha N, Marreaud SI, Stahel RA, Peters S, and Besse B. Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 study. Annals of Oncology 2022;33:(4),451-453. Presented at the ESMO Virtual Plenary March 2022. (ETOP 8-15 PEARLS)

ETOP 10-16 BOOSTER

41. Dafni U, Soo RA, Peters S, Tsourti Z, Vervita K, Han JY, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Angeles Sala González M, Bernabé Caro R, Provencio Pulla M, Cuffe S, Ruepp B, Roschitzki-Voser H, Rosell R, and Stahel RA. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis. Annals of Oncology 2022;33:(Suppl2),S46-S47. Presented at the ELCC 2022, virtual. (ETOP 10-16 BOOSTER)

2021

ETOP 10-16 BOOSTER

40. Soo R, Han J-Y, Dimopoulou G, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabe R, Coate L, Provencio M, García Campelo R, Cuffe S, Hashemi S, Früh M, Ruepp B, Roschitzki-Voser H, Stahel R, and Peters S. A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. Annals of Oncology 2021;32:(7),942-944. Presented at the ESMO Virtual Plenary May 2021 & Virtual Plenary Debate during ESMO Congress 2021. (ETOP 10-16 BOOSTER)

General

39. Peters S, Dafni U, Perol M, Felip E, Polito L, Pal N, Ton TGN, Merritt D, Morris S, and Stahel RA. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data. Annals of Oncology 2021;32:(5),687-688. Presented at the ESMO Virtual Plenary April 2021. (ETOP General)

ETOP Mesoscape

38. Opitz I, Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, Ampollini L, De Perrot M, Brcic L, Nadal E, Gray S, Aerts J, Verbeken E, Silini E, Zaeimi F, Samarzija M, Llatjos R, Tsimpoukis S, Von Der Thüsen J, Finn S, Monkhorst K, Marti N, Dimopoulou G, Kammler R, Peters S, Baas P, and Stahel R. Phosphorylated Ribosomal Protein S6, Correlation With Characteristics and Clinical Outcome in Patients With MPM: Results from ETOP Mesoscape. Journal of Thoracic Oncology 2021;16:(3),152. Presented at the WCLC 2020 in Singapore. (ETOP Mesoscape)

2020

ETOP 14-18 CHESS

37. Guckenberger M, Opitz I, Dafni U, Fontecedro AC, Scherz A, Elicin O, Addeo A, Aerts JGJV, Dingemans AM, Hendriks L, Munarriz BJ, Juan-Vidal O, Sullivan I, Valdivia J, Piguet AC, Roschitzki-Voser H, Ehrbar S, Baumgartl M, Peters S, and Stahel RA. Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial. Annals of Oncology 2020;31:(Suppl4),895-896. Presented at the ESMO Virtual Congress 2020. (ETOP 14-18 CHESS)

ETOP 4-12 STIMULI

36. Peters S, Pujol JL, Dafni U, Dómine M, Becker A, Andrade J, Curioni-Fontecedro A, Molinier O, Moro-Sibilot D, Nackaerts K, Mollá AI, López Vivanco G, Madelaine J, Popat S, Reck M, Roschitzki-Voser H, Mitchell P, De Ruysscher D, Le Pechoux C, and Stahel R. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial. Annals of Oncology 2020;31:(Suppl4),1211. Presented at the ESMO Virtual Congress 2020. (ETOP 4-12 STIMULI)

2019

ETOP Mesoscape

35. Opitz I, Bille A, Tsourti Z, Nakaerts K, Ampollini L, De Perrot M, Brcic L, Nadal E, Gray S, Aerts J, Verbeken E, Silini E, Zaeimi F, Samarzija M, Llatjos R, Tsimpoukis S, Van Der Thüsen JH, Finn S, Marti N, Dimopoulou G, Monkhorst K, Brunello A, Kammler R, Soltermann A, Falcoz P, Baas P, and Stahel R. Realtime Data from Europe ETOP / ESTS Database. Journal of Thoracic Oncology 2019;14:(10),93-94. Presented at the WCLC 2019 in Barcelona, Spain. (ETOP Mesoscape)

ETOP 9-15 PROMISE-meso

34. Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R, O’Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur W-D, López Castro R, García Campelo R, Roschitzki-Voser H, Ruepp B, Rusakiewicz S, Peters S, and Stahel RA. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Annals of Oncology 2019;30:(Suppl5),931. Presented at the ESMO Congress 2019 in Barcelona, Spain. (ETOP 9-15 PROMISE-meso)

ETOP 6-14 NICOLAS

33. Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet A-C, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste JF, and De Ruysscher D. Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial. Annals of Oncology 2019;30:(Suppl5),591. Presented at the ESMO Congress 2019 in Barcelona, Spain. (ETOP 6-14 NICOLAS)

2018

ETOP 5-12 PEARLS

32. Peters S, Danson SJ, Hasan B, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Massutí B, Coate L, von Moos R, Zielinski CC, De Maio E, O’Brien M, Roschitzki-Voser H, Dafni U, and Stahel RA. A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. Annals of Oncology 2018;29:(Suppl8),498. Presented at the ESMO Congress 2018 in Munich, Germany. (ETOP 5-12 SPLENDOUR)

ETOP 2-11 BELIEF

31. Curioni A, Stahel RA, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Karachaliou N, Rosell R, Roschitzki-Voser H, Kammler R, Kassapian M, Felip E, Dafni U, Molina M-A, Gautschi O, Peters S, Massutí B, Palmero R, and Ponce S. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial. Annals of Oncology 2018;29:(Suppl8),513. Presented at the ESMO Congress 2018 in Munich, Germany. (ETOP 2-11 BELIEF)

ETOP 6-14 NICOLAS

30. Peters S, De Ruysscher D, Dafni U, Felip E, Guckenberger M, Vansteenkiste JF, Huber R, Nadal E, Irigoyen A, Becker A, Piguet A-C, Kassapian M, Gasca-Ruchti A, Martinez Marti A, Andratschke N, Lambrecht M, Belka C, Roschitzki-Voser H, and Stahel RA. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial. Journal of Clinical Oncology 2018;36:(Suppl15),8510. Presented at the ASCO Annual Meeting 2018 in Chicago, IL, USA. (ETOP 6-14 NICOLAS)

ETOP Lungscape

29. Van Seijen M, Brcic L, Navarro A, Sansano I, Béndek M, Witte B, Brcic I, Kammler R, Stahel RA, and Thunnissen E. Influence of delayed and prolonged fixation on the evaluation of immunohistochemical staining on pulmonary resection specimen. Journal of Thoracic Oncology 2018;13:(4),11. Presented at ELCC 2018 in Geneva, Switzerland. (ETOP Lungscape)

2017

ETOP Lungscape

28. Thunnissen E, Dafni U, Bubendorf L, Warth A, Biernat W, Pokharel S, Dziadziuszko R, Dienemann H, Cheney R, Marti N, Kassapian M, Finn S, Kerr K, Kammler R, Stahel R, Peters S, and ETOP Lungscape. Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort. Journal of Thoracic Oncology 2017;12:(11),1821-1822. Presented at the WCLC 2017 in Yokohoma, Japan. (ETOP Lungscape)

ETOP Lungscape

27. Kerr KM, Thunnissen E, Dafni U, Soltermann A, Finn S, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E-J, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Polydoropoulou V, Kammler R, Peters S, and Stahel RA. Association of programmed cell death 1 ligand (PD-L1) expression with molecular alterations in non-small cell lung cancer (NSCLC) patients (pts): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Annals of Oncology 2017;28:(Suppl5),573–594. Presented at the ESMO Congress 2017 in Madrid, Spain. (ETOP Lungscape)

ETOP Lungscape

26. Kerr K, Thunnissen E, Dafni U, Soltermann A, Finn S, Bubendorf L, Verbeken E, Biernat W, Warth A, Marchetti A, Speel E-J, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Bille Madsen L, Polydoropoulou V, Kammler R, Peters S, and Stahel RA. Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Journal of Clinical Oncology 2017;35:(Suppl15),8516. Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA. (ETOP Lungscape)

ETOP 7-14 NICHE

25. Smit EF, Peters S, Dziadziuszko R, Dafni U, Wolf J, Wasąg B, Biernat W, Finn S, Kammler R, Tsourti Z, Rabaglio-Poretti M, Ruepp BU, Roschitzki-Voser H, Stahel RA, and Felip E. A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial. Journal of Clinical Oncology 2017;35:(Suppl15),9070-9070. Presented at the ASCO Annual Meeting 2017 in Chicago, IL, USA. (ETOP 7-14 NICHE)

ETOP 6-14 NICOLAS

24. Peters S, Stahel RA, Kassapian M, Guckenberger M, Felip E, De Langen AJ, Huber R, Piguet A-C, Roschitzki-Voser H, and De Ruysscher D. A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial. Annals of Oncology 2017;28:(Suppl2),27. Presented at ELCC 2017 in Geneva, Switzerland. (ETOP 6-14 NICOLAS)

ETOP Lungscape

23. Finn S, Letovanec I, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel E-J, Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernández-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, and Stahel R. Evaluation of NGS and RT-PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project. Journal of Thoracic Oncology 2017;12:(11,Suppl1),501-502. Presented at the WCLC 2016 in Vienna, Austria. (ETOP Lungscape)

2016

ETOP 4-12 STIMULI

22. De Ruysscher D, Pujol J-L, Popat S, Reck M, Le Pechoux C, Liston A, Speiser D, Coukos G, Kammler R, Dafni U, Tsourti Z, Roschitzki H, Finlayson M, Piguet A-C, Ruepp B, Maibach R, Stahel RA, and Peters S. STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT. Annals of Oncology 2016;27:(Suppl6),493–496. Presented at the ESMO Congress 2016 in Copenhagen, Denmark. (ETOP 4-12 STIMULI)

ETOP Lungscape

21. Soltermann A, Rulle U, Dafni O, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen Bille L, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn S, Kammler R, Schulze K, Bubendorf L, and Stahel RA. Prevalence and clinical associations of PTEN loss in non-small cell lung carcinoma (NSCLC) patients (pts) of the European Thoracic Oncology Platform (ETOP) Lungscape cohort. Annals of Oncology 2016;27:(Suppl6),526–544. Presented at the ESMO Congress 2016 in Copenhagen, Denmark. (ETOP Lungscape)

ETOP 2-11 BELIEF

20. Rosell R, Karachaliou N, Giménez-Capitán A, Codony-Servat C, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Ponce-Aix S, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Favaretto A, Kammler R, Dafni U, Tsourti Z, Molina-Vila MA, and Stahel RA. The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. Cancer Research 2016;76:(14,Suppl),269-269. Presented at the Annual Meeting of the AACR 2016, New Orleans, LA, USA. (ETOP 2-11 BELIEF)

2015

ETOP 2-11 BELIEF

19. Stahel RA, Dafni U, Gautschi O, Felip E, Curioni-Fontecedro A, Peters S, Massutí B, Cardenal F, Aix SP, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Carcereny E, Sanchez Ronco M, Molina MA, and Rosell R. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. European Journal of Cancer 2015;51:(Suppl3),711-712. Presented at the European Cancer Congress 2015 in Vienna, Austria. (ETOP 2-11 BELIEF)

ETOP Lungscape

18. Kerr K, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Gately K, Biernat W, Vliegen L, Hernandez Losa J, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Molina MA, Shames DS, Peters S, and Stahel R. Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. European Journal of Cancer 2015;51:(Suppl3),595-596. Presented at the European Cancer Congress 2015 in Vienna, Austria. (ETOP Lungscape)

ETOP Lungscape

17. Bubendorf L, Dafni U, Finn S, Warth A, Savic S, Thunnissen E, Sejda A, Verbeken E, Tischler V, Marchetti A, Sansano I, Speel E, Cheney R, Nonaka D, Monkhorst K, Di Lorito A, Consuelo Calabuig M, Reidy M, Hager H, Mathieson W, Martorell M, Baas P, Dienemann H, Smit E, Blackhall F, Dingemans A, Felip E, Adjei A, Meldgaard P, Weder W, Vansteenkiste J, Dziadziuszko R, Tsourti Z, Kerr K, Schulze K, Das-Gupta A, Peters S, and Stahel R. Prevalence and Clinical Association of MET Gene Amplification in Patients with NSCLC: Results from the ETOP Lungscape Project. Journal of Thoracic Oncology 2015;10:(9,Suppl2),173-260. Presented at the WCLC 2015 in Denver, CO, USA. (ETOP Lungscape)

ETOP Lungscape

16. Letovanec I, Peters S, Tsourti Z, Finn S, Soltermann A, Bubendorf L, Speel E, Marchetti A, Nonaka D, Hager H, Martorell M, Monkhorst K, Sejda A, Cheney R, Sansano I, Verbeken E, Tischler V, Savic S, Di Lorito A, Consuelo Calabuig M, Felip E, Adjei A, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans A, Dienemann H, Dziadziuszko R, Vansteenkiste J, Kammler R, Dafni U, Kerr K, Thunnissen E, and Stahel R. Evaluation of RT-PCR Methodology for ALK Assessment in Patients with NSCLC in Europe: Results from the ETOP Lungscape Project. Journal of Thoracic Oncology 2015;10:(9,Suppl2),407-760. Presented at the WCLC 2015 in Denver, CO, USA. (ETOP Lungscape)

ETOP 3-12 EMPHASIS

15. Peters S, Smit EF, Dafni U, Aix SP, Massuti B, Gautschi O, Coate L, Martín AL, van Heemst R, Berghmans T, Meldgaard P, Dols MC, Noguera JG, Floriani IC, Kassapian M, Kuruvilla YCK, Gasca-Ruchti A, Zielinski C, Gregorc V, and Stahel RA. Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial. Journal of Clinical Oncology 2015;33:(Suppl15),8049-8049. Presented at the ASCO Annual Meeting 2015 in Chicago, IL, USA. (ETOP 3-12 EMPHASIS)

2014

ETOP Lungscape

14. Bubendorf L, Savic S, Dafni O, Tsourti Z, Tischler V, Finn S, Biernat W, Verbeken E, Hager H, Murtra N, Thunnissen E, Nonaka D, Warth A, Speel EJ, Martorell M, Schulze K, Das-Gupta A, Kerr KM, Peters S, and Stahel RA. Prevalence and clinical outcomes for patients with MET protein expression in patients with non-small cell lung cancer in Europe: Results from the European Thoracic Oncology Platform Lungscape Project. Annals of Oncology 2014;25:(Suppl4),418-418. Presented at the ESMO Congress 2014 in Madrid, Spain. (ETOP Lungscape)

2013

ETOP Lungscape

13. Peters S, Weder W, Meldgaard P, O'Byrne K, Wrona A, Dooms C, Hernandez-Losa J, Marchetti A, Nicolson M, Tan Q, Smit EF, Dingemans A-MC, Savic S, Blackhall FH, Baas P, Jantus-Lewintre E, Kerr KM, Dafni U, Rafael R, and Stahel RA. The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. Journal of Clinical Oncology 2013;31:(Suppl15),7514-7514. Presented at the ASCO Annual Meeting 2013 in Chicago, IL, USA. (ETOP Lungscape)

ETOP Lungscape

12. Kerr K, Thunnissen E, Blackhall F, Dafni U, Bubendorf L, Hager H, Soltermann A, O'Byrne K, Marchetti A, Dooms C, Sejda A, Sansano I, Nonaka D, Cheney R, De Jong J, Speel E, Jantus-Lewintre E, Zhang Y, Stahel R, and Peters S. ALK immunohistochemistry and fluorescence in-situ hybridization in lung adenocarcinomas from the ETOP Lungscape tumour cohort. Journal of Thoracic Oncology 2013;8:(11,Suppl2),2-1348. Presented at the 15th WCLC 2013 in Sydney, Australia. (ETOP Lungscape)

2012

ETOP Lungscape

11. Peters S, Dafni U, Bubendorf L, Meldgaard P, O'Byrne K, Wrona A, Weder W, Canela M, Malatesta S, Vansteenkiste J, Dingemans A, Nicolson M, Savic S, Baas P, Peck R, Lu S, Smit E, Jantus-Lewintre E, Rosell R, and Stahel R. The European Thoracic Oncology Platform Lungscape project. A way to bridge non-small cell lung cancer molecular characteristics and clinical data. Annals of Oncology 2012;23:(Suppl9),385. Presented at the ESMO Congress 2012 in Vienna, Austria. (ETOP Lungscape)

ETOP Lungscape

10. Blackhall F, Peters S, M. Kerr K, O'Byrne K, Hager H, Sejda A, Soltermann A, Dooms C, Felip E, Marchetti A, M. Speel EJ, Price N, Savić S, de Jong J, Martorell M, Thunnissen E, Bubendorf L, Dafni U, Rosell R, and Stahel RA. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: Preliminary results from the European Thoracic Oncology Platform Lungscape project. Annals of Oncology 2012;23:(Suppl9),73. Presented at the ESMO Congress 2012 in Vienna, Austria. (ETOP Lungscape)

General

9. Stahel R. Lung Cancer: The European Thoracic Oncology Platform. Annals of Oncology 2012;23:(Suppl9),58. Presented at the ESMO Congress 2012 in Vienna, Austria. (ETOP General)

ETOP Lungscape

8. Normanno N, Patton S, Blackhall F, Murray S, Kerr K, Dietel M, Filipits M, Benlloch S, Stahel R, and Thunnissen E. Results of the second pilot external quality assurance scheme for somatic EGFR mutation testing in non-small cell lung cancer (NSCLC). Annals of Oncology 2012;23:(Suppl9),86. Presented at the ESMO Congress 2012 in Vienna, Austria. (ETOP Lungscape)

ETOP Lungscape

7. Thunnissen E, Kerr K, Bubendorf L, Nonaka D, Blackhall F, Kammler R, Speel E, De Jong J, Martorell M, and Stahel R. External quality assessment for ALK immunohistochemistry testing in lung adenocarcinoma within the European Thoracic Oncology Platform Lungscape project. Annals of Oncology 2012;23:(Suppl9),80. Presented at the ESMO Congress 2012 in Vienna, Austria. (ETOP Lungscape)

ETOP Lungscape

6. Stahel R, Blackhall F, Peters S, Bubendorf L, Dafni U, Kerr K, Taron M, Thunnissen E, Weder W, and Rosell R. The Lungscape project. Journal of Thoracic Oncology 2012;7:(6,Suppl1),13. Presented at ELCC 2012 in Geneva, Switzerland. (ETOP Lungscape)

General

5. Stahel RA, Peters S, Blackhall F, Bubendorf L, Dafni U, Kerr K, Taron M, Thunnissen E, Weder W, Smit E, and Rosell R. ETOP activity in the field of biomarkers and predictors. Lung Cancer 2012;77:(Suppl1),16-17. Presented at BTOG 2012 in Dublin, Ireland. (ETOP General)

ETOP Lungscape

4. Peters S, Blackhall F, Taron M, Rosell R, Hiltbrunner A, Maibach R, King R, and Stahel R. ETOP Data system: Combining the comprehensive Lungscape database with a clinical trails platform. Annals of Oncology 2012;23:(Suppl1),41. Presented at TAT 2012 in Amsterdam, the Netherlands. (ETOP Lungscape)

2011

ETOP Lungscape

3. Blackhall F, Peters S, Kerr K, Kulig K, Bubendorf L, Thunnissen E, Dziadziuszko R, O’Byrne K, Baas P, Weder W, Taron M, Rosell R, and Stahel R. ALK Gene Rearrangement: Prevalence and clinical outcomes in patients with non-small cell lung cancer (NSCLC) in Europe – A European Thoracic Oncology Group (ETOP) Lungcape Study. Journal of Thoracic Oncology 2011;6:(6,Suppl2),1529-1530. Presented at the 14th WCLC 2011 in Amsterdam, the Netherlands. (ETOP Lungscape)

ETOP Lungscape

2. Peters S, Blackhall F, Boffetta P, Kerr K, Taron M, Bubendorf L, Ciardiello F, Rosell R, Weder W, King R, and Stahel R. Building a Comprehensive Database for the Lungscape Project: A Way to Bridge Genomics and Clinical Practice in the European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology 2011;6:(6,Suppl2),994-995. Presented at the 14th WCLC 2011 in Amsterdam, the Netherlands. (ETOP Lungscape)

ETOP Lungscape

1. Stahel R, Blackhall F, Peters S, Kerr K, Taron M, Bubendorf L, Weder W, Boffetta P, Ciardiello F, and Rosell R. Lungscape - a project of the European Thoracic Oncology Platform (ETOP). Annals of Oncology 2011;22:(Suppl3),28. Presented at the Annals of Oncology, Presented at TAT 2011 in Paris, France. (ETOP Lungscape)